Global Erythromycin Market Size, Share, and COVID-19 Impact Analysis, By Product Type (Erythromycin Capsules, Erythromycin Topical, Erythromycin Oral Suspension, Erythromycin Injection, and Erythromycin Tablets), By Application (Skin Infections, Gastrointestinal Infections, Respiratory Tract Infections, Genital Infections, and Others), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 - 2033

Global Erythromycin Market Insights Forecasts to 2033

• The Global Erythromycin Market Size was Estimated at USD 11.98 Billion in 2023
• The Market Size is Expected to Grow at a CAGR of around 5.48% from 2023 to 2033
• The Worldwide Erythromycin Market Size is Expected to reach USD 20.43 Billion by 2033
• Asia Pacific is predicted to Grow at the fastest CAGR throughout the projection period

The Global Erythromycin Market Size is predicted to Exceed USD 20.43 Billion by 2033, Growing at a CAGR of 5.48% from 2023 to 2033. The market growth is facilitated by the rising occurrence of bacterial infection, the growing magnitude of clinical trials and research and development activities, the increasing production of generic medications, and technological innovations in drug discovery.

Market Overview

The erythromycin market aims to develop and commercialize erythromycin medications for the treatment of bacterial infections. Erythromycin is a natural antibiotic derived from Streptomyces erytreus, which is classified under macrolide antibiotics and has anti-bacterial activity. Erythromycin is a bacteriostatic antibiotic that prevents the growth of bacteria, acting against gram-positive and gram-negative bacteria. It is available in pink, unscored oval tablets and can be administered via intravenous, topical, and ophthalmic routes. Erythromycin is used to prevent and treat various body infections, including those of the respiratory tract, skin, diphtheria, intestinal amebiasis, acute pelvic inflammatory disease, Legionnaire's disease, pertussis, and syphilis. It also prevents recurrent rheumatic fever attacks in patients allergic to penicillin or sulfa drugs. The marketed products of erythromycin are Erythrowell-250 tablet, ErythroCare Oral Suspension, Erymicin 200 injection, etc.

Several government initiatives, such as control and awareness programs of bacterial infections, contribute to the market expansion. For instance, in India, Ministry of Health and Family Welfare launched the Social Awareness and Actions to Neutralize Pneumonia Successfully (SAANS) in 2019, aims to reduce childhood pneumonia deaths by promoting awareness about preventive, treatment, and early identification, and implementing a campaign in states/UTs annually to accelerate action against this disease, thereby enhancing care seeking behaviours among parents and caregivers. Hence, the rising diagnosis and treatment of pneumonia caused by bacteria or fungi accelerates the utilization of the erythromycin medications, which results in market growth.

The rising cases of pneumonia drive the market. Erythromycin is the first-line drug to treat pneumonia caused by bacteria and fungi. For example, data provided by the World Health Organization states that pneumonia is the leading cause of child deaths globally, with 740,180 children under the age of 5 died in 2019. It accounts for 14% of all deaths in children under 5 but 22% in 1–5-year-olds. The disease affects children worldwide, with the highest rates in southern Asia and sub-Saharan Africa. Therefore, increasing pneumonia patients accelerates the hospitalization rate for the diagnosis and treatment of pneumonia, which leads to the increasing demand of the antibiotics, particularly erythromycin as it is effective and safe which results in the expansion of the erythromycin market. The most commonly used marketed product of erythromycin for children is Althrocin Drops.

The increasing cases of bacterial skin infections leading to increasing demand for the topical treatment of skin infections escalates the market growth. Bacterial skin diseases and inflammatory conditions caused by bacterial infections pose a significant global disease burden. For instance, the data published in the Archives of Dermatological Research indicates that the highest incidence rate is in low socio-demographic regions and populations under 35. The disability adjusted life years rate increased from 20.82 per 100,000 in 1990 to 25.45 per 100,000 in 2021, with a -0.11 % average annual percent change. The highest increase is in high SDI regions and populations over 85. The incidence cases reached nearly 90 million in 2021 and are expected to reach 1.2 billion in 2045. Consider all the optimistic features of erythromycin fuels the growth of the market and is projected to exceed USD 20.43 billion by 2033.

Report Coverage

This research report categorizes the global erythromycin market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyzes the key growth drivers, opportunities, and challenges influencing the global erythromycin market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyzes their core competencies in each sub-segment of the global erythromycin market.

Driving Factors:

Increasing proportion of aged population and rising consumption of erythromycin medications:

The upsurge in the geriatric population is driving a rising demand for erythromycin owing to increased vulnerability to bacterial infections. Common infections among aged populations include respiratory tract, skin, and urinary tract infections. Erythromycin is being used to treat respiratory tract infections like common cold, laryngitis, pharyngitis, rhinitis, rhinosinusitis, otitis media, bronchitis, pneumonia, and tracheitis. The need for effective antibiotics to combat these infections is driving the global demand for erythromycin.

Rising occurrence of bacterial infections:

The global increase in bacterial infections is accelerating the demand for erythromycin, an antibiotic effective against various bacteria. It is crucial for treating respiratory tract, skin, and sexually transmitted diseases. Healthcare providers rely on erythromycin for its broad-spectrum efficacy, and the global healthcare system's focus on reducing bacterial infections further fuels the erythromycin market's growth. The persistent health challenge of bacterial infections necessitates the continuous need for effective antibiotics like erythromycin.

Restraining Factors

Erythromycin's market growth is hindered by its side effects, including nausea, vomiting, and diarrhea, and interactions with other medications, potentially leading to dangerous cardiac arrhythmias. The market is constrained from generic competition, resulting in price erosion due to the availability of multiple products.

Market Segmentation

The global erythromycin market share is classified into product type, application, and distribution channel.

• The erythromycin tablets segment dominated the market with 42.74% of the share in 2023 and is anticipated to grow at a significant CAGR throughout the forecast period.

Based on the product type, the global erythromycin market is categorized into erythromycin capsules, erythromycin topical, erythromycin oral suspension, erythromycin injection, and erythromycin tablets. Among these, the erythromycin tablets segment dominated the market with 42.74% of the share in 2023 and is anticipated to grow at a significant CAGR throughout the forecast period. The segmental expansion is attributed to its effectiveness against a wide range of bacterial infections, patient convenience, precise dosing, the masking effect of the tablet that avoids the unpleasant taste, ease of administration, safer drug for children, and extended shelf life.

• The respiratory tract infection segment accounted for the largest market share of 34.16% in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.

Based on the application, the global erythromycin market is categorized into skin infections, gastrointestinal infections, respiratory tract infections, genital infections, and others. Among these, the respiratory tract infection segment accounted for the largest market share of 34.16% in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. The segment's growth is attributed to the increasing prevalence of respiratory tract infections such as pneumonia, bronchitis, and pertussis, and exerting effective antibacterial activity against gram-positive bacteria.

• The hospital pharmacies segment held the largest market share of 47.11% in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.

Based on the distribution channel, the global erythromycin market is categorized into retail pharmacies, hospital pharmacies, and online pharmacies. Among these, the hospital pharmacies segment held the largest market share of 47.11% in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. This segment dominance is ascribed to the availability of a wide stock of antibiotics, provision of the compounding and dispensing of medications, immediate accessibility of the medications, cost-effective drugs, providing dosage regimen, and guidance from the hospital pharmacists, which reduces the risk of medication errors.

Regional Segment Analysis of the Global Erythromycin Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the global erythromycin market over the predicted timeframe.

North America is anticipated to hold the largest share of the global erythromycin market over the predicted timeframe. This is attributed to the increasing prevalence of skin infections, rising research and development activities, and the rising proportion of the geriatric population. The growing magnitude of Food and Drug Administration (FDA) approval and growing production and adoption of generic medicines, rising healthcare expenditure.

Asia Pacific is anticipated to grow at the fastest CAGR throughout the projected timeframe. This is owing to rapid industrialization, saturation of the manufacturing companies of antibiotics, increasing number of clinical trials, rising population, growing medical treatment demand, expansion in the antibiotic sales, and rising occurrence of the bacterial infections.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global erythromycin market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Sanofi S.A.
• Alembic Pharmaceuticals Limited
• Hikma Pharmaceuticals Plc.
• Lupin Limited
• Astellas Pharma Inc.
• Cipla Limited
• Akorn, Inc.
• Teva Pharmaceuticals Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Abbott Laboratories
• Zydus Cadila
• Eli Lilly Company
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In April 2022, Nexus Pharmaceutical developed the Erythromycin Lactobionate for Injection (USP in 500mg/vial). The launch demonstrates Nexus's commitment to providing critical antibiotics when they are needed most. The antibiotic is the first of many upcoming products to be provided by Nexus as it continues to boost domestic medication production. It is available in cartons of five single-dose vials.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global erythromycin market based on the below-mentioned segments:

Global Erythromycin Market, By Product Type

• Erythromycin Capsules
• Erythromycin Topical
• Erythromycin Oral Suspension
• Erythromycin Injection
• Erythromycin Tablets

Global Erythromycin Market, By Application

• Skin Infections
• Gastrointestinal Infections
• Respiratory Tract Infections
• Genital Infections
• Others

Global Erythromycin Market, By Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

Global Erythromycin Market, By Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa